Effect of lisinopril on circulating endothelial progenitor cells in patients with essential hypertention
https://doi.org/10.18705/1607-419X-2011-17-5-493-500
Abstract
Objective. To assess the effect of lisinopril on the dynamics of circulating endothelial progenitor cells (EPC) as well as the clinical markers of cardiovascular risk in patients with essential hypertension. Design and methods. We have studied the number and functional activity of EPC and clinical markers of cardiovascular risk in carefully selected group of 18 patients with essential hypertension, who have never been treated by angiotensin converting enzyme inhibitors (ACEi), and 19 normotensive control subjects. Hypertensive patients took lisinopril in dose 10-20 mg daily and then were re-examined after 12 weeks of lisinopril therapy. Results. The present study shows that hypertensive patients are characterized by a relative decline in the number of circulating EPC in conditions of endothelial dysfunction. Also the cells with angiogenic potential have a decreased proliferative capacity in hypertensive patients in comparison with healthy controls (1,4 ± 0,9 vs 2,2 ± 1,2 units/mm2; p < 0,01). Changes of the functional activity of EPC are closely associated with pathological vascular remodeling. Conclusions. ACEi lisinopril improves functional properties of the endothelium in hypertensive patients through mobilizing effect on the EPC and stimulates their proliferation activity.
About the Authors
E. V. Karelkina
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
O. B. Irtuga
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
V. S. Moroshkin
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
A. V. Selutin
Ott's Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
P. S. Kozlov
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
O. A. Bystrova
Institute of Cytology RAS
Russian Federation
Russian Federation
O. M. Moiseeva
Almazov Federal Heart, Blood and Endocrinology Centre
Russian Federation
Russian Federation
References
1. Шальнова С.А., Деев А.Д., Оганов Р.Г. и др. Роль систолического и диастолического давления для прогноза смертности от сердечнососудистых заболеваний // Кардиоваск. терапия и профилактика. — 2002. — № 1. — С. 10-15.
2. Moser M., Hebert P.R. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials // J. Am. Coll. Cardiol. — 1996. — Vol. 27, № 5. — P. 1214-1218.
3. JNC-VII: The seventh report of the joint national committee on prevention, detection, evaluation and treatment of high blood pressure // J. Am. Med. Assoc. — 2003. — Vol. 289, № 19. — Р. 2560-2571.
4. Meredith P.A., Östergren J. Are there better primary prevention strategies? Review: from hypertension to heart failure // J. Renin-Angiotensin-Aldosterone Syst. — 2006. — Vol. 7, № 2. — P. 64-73.
5. Thybo N.K., Korsgaard N., Eriksen S. et al. Dose-dependent effects of perindopril on blood pressure and on small artery structure // Hypertension. — 1994. — Vol. 23, № 5. — Р. 659-666.
6. Sharifi A.M., Li J.S., Endemann D., Schiffrin E.L. Effects of enalapril and amlodipine on small-artery structure and composition, and on endothelial dysfunction in spontaneously hypertensive rats // J. Hypertens. — 1998. — Vol. 16, № 4. — Р. 457-466.
7. Scheidegger K.J., Wood J.M., Van Essen H. et al. Effects of prolonged blockade of the renin angiotensin system on striated muscle microcirculation of spontaneously hypertensive rats // J. Pharmacol. Exp. Ther. — 1996. — Vol. 278, № 3. — Р. 1276-1281.
8. Yoshiji H., Kuriyama S., Kawata M. et al. The angiotensin-I- converting enzyme inhibitor Perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor // Clin. Cancer Res. — 2001. — Vol. 7, № 4. — Р. 1073-1078.
9. Le Noble F.A.C., Stassen F.R.M., Hacking W.J.G. et al. Angiogenesis and hypertension // J. Hypertens. — 1998. — Vol. 16, № 11. — Р. 1563-1572.
10. Isner J.M., Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization // J. Clin. Invest. — 1999. — Vol. 103, № 9. — Р. 1231-1236.
11. Hristov M., Erl W., Weber P.C. Endothelial progenitor cells: mobilization, differentiation, and homing // Arterioscler. Thromb. Vasc. Biol. — 2003. — Vol. 23, № 7. — Р. 1185-1189.
12. Urbich C., Dimmeler St. Endothelial progenitor cells. Characterization and role in vascular biology // Cir. Res. — 2004. — Vol. 95, № 4. — Р. 343-353.
13. Brunner H., Cockcroft J.R., Deanfield J. et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society ofHypertension // J. Hypertens. — 2005. — Vol. 23, № 2. — Р. 233-246.
14. Hill J.M., Zalos G., Halcox J.P.J. et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk // N. Engl. J. Med. — 2003. — Vol. 348, № 7. — Р. 593-600.
15. Werner N., Kosiol S., Schiegl T. et al. Circulating endothelial progenitor cells and cardiovascular outcomes // N. Engl. J. Med. — 2005. — Vol. 353, № 10. — Р. 999-1007.
16. Кобалава Ж.Д., Котовская Ю.В. Мониторирование артериального давления: методические аспекты и клиническое значение / Под ред. В.С. Моисеева. — М.: Издательская группа «Сервье», 1999. — 234 c.
17. Devereux R.B., Reinchek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method // Circulation. — 1977. — Vol. 55, № 4. — Р. 613-618.
18. Lang R.M., Bierig M., Devereux R.B., Flachskampf F.A. et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology // J. Am. Soc. Echocardiogr. — 2005. — Vol. 18, № 12. — Р. 1440-1463.
19. Celermajer D.S., Soresen K.E., Gooch V.M. et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis // Lancet. — 1992. — Vol. 340, № 8828. — Р. 1111-1115.
20. Vogel R.A. Measurement of endothelial function by brachial artery flow-mediated vasodilatation // Am. J. Cardiol. — 2001. — Vol. 88, № 2A. — Р. 31E-34E.
21. Timmermans F., Plum J., Yöder M.C. et al. Endothelial progenitor cells: identity defined? // J. Cell. Mol. Med. — 2009. — Vol. 13, № 1. — Р. 87-102.
22. Watt S.M., Athanassopoulos A., Harris A.L., Tsaknakis G. Human endothelial stem/progenitor cells, angiogenic factors and vascular repair // J. R. Soc. Interface. — 2010. — Vol. 7, suppl. 6. — P. S731-S751.
23. Ballard V.L., Edelberg J.M. Stem cells for cardiovascular repair — the challenges of the aging heart // J. Mol. Cell. Cardiol. — 2008. — Vol. 45, № 4. — Р. 582-592.
24. Peichev M., Naiyer A.J., Pereira D. et al. Expression of VEGFR-2 and AC133 by circulating human CD34+ cells identifies a population of functional endothelial precursors // Blood. — 2000. — Vol. 95, № 3. — Р. 952-958.
25. Case J., Mead L.E., Bessler W.K. et al. Human CD34+AC133+ VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors // Exp. Hematol. — 2007. — Vol. 35, № 7. — Р. 1109-1118.
26. Hoetzer G.L., Van Guilder G.P., Irmiger H.M. et al. Aging, exercise, and endothelial progenitor cell clonogenic and migratory capacity in men // Appl. Physiol. — 2007. — Vol. 102, № 3. — Р. 847-852.
27. Bellows C.F., Zhang Y., Simmons P.J., Khalsa A.S., Kolonin M.G. Influence of BMI on level of circulating progenitor cells // Obesity (Silver Spring). — 2011. — Vol. 19, № 8. — Р. 1722-1726.
28. Psaltis P.J., Zannettino A.C., Worthley S.G., Gronthos S. Concise review: mesenchymal stromal cells: potential for cardiovascular repair // Stem Cells. — 2008. — Vol. 26, № 9. — Р. 2201-2210.
29. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains // Exp. Cell. Res. — 1961. — Vol. 25. — P. 585-621.
30. Chen J., Goligorsky M.S. Premature senescence of endothelial cells: Methusaleh's dilemma // Am. J. Physiol. Heart Circ. Physiol. — 2006. — Vol. 290, № 5. — Р. H1729-H1739.
31. Verma S., Kuliszewski M.A., Shu-Hong Li. et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation and function // Circulation. — 2004. — Vol. 109, № 17. — Р. 2058-2067.
Review
For citations:
Karelkina E.V., Irtuga O.B., Moroshkin V.S., Selutin A.V., Kozlov P.S., Bystrova O.A., Moiseeva O.M. Effect of lisinopril on circulating endothelial progenitor cells in patients with essential hypertention. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(5):493-500. (In Russ.) https://doi.org/10.18705/1607-419X-2011-17-5-493-500
Views:
1024
Email this article 